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Abstract
Background: RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for
numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the
potential of different oligonucleotide-based strategies for silencing the genes responsible for several polyQ
diseases, including Huntington’s disease and two spinocerebellar ataxias, type 1 and type 3. The strategies included
nonallele-selective gene silencing, gene replacement, allele-selective SNP targeting and CAG repeat targeting.
Results: Using the patient-derived cell culture models of polyQ diseases, we tested various siRNAs, and antisense
reagents and assessed their silencing efficiency and allele selectivity. We showed considerable allele discrimination
by several SNP targeting siRNAs based on a weak G-G or G-U pairing with normal allele and strong G-C pairing
with mutant allele at the site of RISC-induced cleavage. Among the CAG repeat targeting reagents the strongest
allele discrimination is achieved by miRNA-like functioning reagents that bind to their targets and inhibit their
translation without substantial target cleavage. Also, morpholino analog performs well in mutant and normal allele
discrimination but its efficient delivery to cells at low effective concentration still remains a challenge.
Conclusions: Using three cellular models of polyQ diseases and the same experimental setup we directly
compared the performance of different oligonucleotide-based treatment strategies that are currently under
development. Based on the results obtained by us and others we discussed the advantages and drawbacks of
these strategies considering them from several different perspectives. The strategy aimed at nonallele-selective
inhibiting of causative gene expression by targeting specific sequence of the implicated gene is the easiest to
implement but relevant benefits are still uncertain. The gene replacement strategy that combines the nonallele-
selective gene silencing with the expression of the exogenous normal allele is a logical extension of the former
and it deserves to be explored further. Both allele-selective RNAi approaches challenge cellular RNA interference
machinery to show its ability to discriminate between similar sequences differing in either single base substitutions
or repeated sequence length. Although both approaches perform well in allele discrimination most of our efforts
are focused on repeat targeting due to its potentially higher universality.
Keywords: Triplet repeats, Polyglutamine diseases, siRNA, Antisense oligonucleotides, SNP targeting, CAG repeat
targeting
Background
PolyQ diseases, which are caused by the expansion of
CAG repeats in the translated sequences of different
genes, include Huntington’s disease (HD), several spino-
cerebellar ataxias (SCAs), dentatorubral pallidoluysian
atrophy (DRPLA) and spinal bulbar muscular atrophy
(SBMA) [1]. The expansion of a repeated sequence in
DNA results in the formation of mutant transcripts and
the translation of mutant proteins containing polyQ
tracts, which leads to the degeneration of neurons
within specific regions of the brain and spinal cord in
some cases [2,3]. The pathogenesis of polyQ diseases is
triggered by a single mutant allele of the implicated
gene acting in a dominant “gain-of-function” fashion [4].
Mutant protein toxicity is considered to be main
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pathogenic factor, but mutant transcripts may also con-
tribute to the pathogenesis [5-8].
RNAi is a powerful tool for specific silencing of dis-
ease-causing genes [9]. The introduction of RNAi
reagents, mainly short interfering RNAs (siRNAs) or
short hairpin RNAs (shRNAs), into cells leads to the
sequence-specific cleavage of transcripts containing the
complementary sequences by RNA-induced silencing
complexes (RISCs) [10,11].
The nonallele-specific silencing of genes causing HD
and SCA3 was shown to be beneficial in rodent models
of these diseases, suggesting that a partial loss of normal
protein function can be tolerated [12-15]. Other studies
suggest that for some polyQ disorders, the wild-type
normal protein expression is required for cellular func-
tion, indicating that allele-specific therapeutic strategies
would be more appropriate [16-18]. Because the effect
of the efficient silencing of both alleles of a specific gene
in human cells is difficult to predict, the allele-specific
inhibition of the mutant gene expression is considered a
safer and more promising strategy for causative thera-
pies. For polyQ diseases, the transcript regions that dis-
tinguish the alleles can be targeted by RNAi reagents:
single-nucleotide polymorphisms (SNPs) linked to
repeat expansions or the repeat region itself. SNP target-
ing has been previously described for HD [19-23], SCA3
[24-26] and SCA7 [27]. The low frequency of suitable
allele-distinguishing SNPs in the human population lim-
its this strategy; therefore, prospective treatments must
be tailored to individual patients. Several authors have
shown that targeting several selected SNPs can be
applied to the majority of HD patients [20,28,29]. Tar-
geting the repeat region by RNAi reagents could offer a
therapeutic approach for all polyQ diseases, but CAG-
repeat-targeting siRNAs have insufficient allele-discrimi-
nating properties [26,30]. Allele-specific inhibition of the
proteins implicated in HD and SCA3 has been demon-
strated with repeat-targeting antisense PNA (peptide
nucleic acid) and LNA (locked nucleic acid) oligomers
[31,32] and miRNA (microRNA)-like RNA duplexes
[30,33].
Determining the most effective and safe potential
treatment of each specific polyQ disease is difficult. In
this study, we tested several oligonucleotide-based stra-
tegies for selected CAG-repeat-containing genes. We
discuss the advantages and disadvantages of the different
approaches. We targeted the HTT, ATXN3 and ATXN1
genes, which are implicated in HD, SCA3 and SCA1,
respectively. In our experimental setup, we used cell cul-
ture models to evaluate the effect of the different strate-
gies on endogenously expressed targets instead of an
artificial exogene targeting system. We discuss the
potential of each approach for use in further testing.
Results and discussion
Nonallele-selective silencing by targeting specific HTT
sequences
Gene silencing without discrimination of alleles can be
achieved by RNAi-based targeting of a specific sequence
within a gene. We analyzed HTT silencing by typical
RNAi reagents in a cellular model of HD. We used a
fibroblast cell line (GM04281, 17/68 CAG in HTT
mRNA) to compare the silencing efficiencies of different
HTT-specific siRNAs (Additional file 1: Figure S1A).
First, siRNA HD1 was transfected at 50 nM. The HTT
mRNA and protein levels were assessed using RT-PCR
and western blot, respectively, at the indicated time
points (Additional file 1: Figure S1B, C). A substantial
decrease in HTT mRNA to ~25% of the control level
was observed 24 h after transfection. After 72 h, the
level of transcript began to slowly increase (Additional
file 1: Figure S1B). A strong reduction in the level of
HTT protein occurred 48 h after transfection, and the
levels remained low for at least the next 6 days (Addi-
tional file 1: Figure S1C). As expected, no allele discri-
mination of HTT silencing by a specific siRNA was
observed.
All three HTT-specific siRNAs (HD1, HD2 and HD3)
contained 21-nt strands, and their targets were located
within the HTT mRNA portion encoded by exon 1. The
specific siRNAs tested showed similar silencing activities
on the HTT transcripts (Additional file 1: Figure S1D).
The efficiency of the inhibition of the mutant HTT pro-
tein was tested for HD1 siRNA at different concentra-
tions (Additional file 1: Figure S1E). HD1 induced an
approximately 50% reduction of the HTT protein level
at 2 nM and an approximately 75% reduction at 50 nM.
As shown previously by others and in our experiments
with the three siRNAs, effective HTT silencing can be
easily achieved in cell culture models and in mouse
models of HD [34,35]. This kind of reagent can be easily
converted into shRNA for the induction of long-term
silencing effects [36,37].
Interestingly, the nonallele-specific silencing of HTT
was shown to provide several benefits in rodent models
of HD [13,14] and in nonhuman primates [38]. The
authors reported improved motor coordination and sur-
vival in HD mice after silencing of both htt alleles and
well-tolerated reduced levels of endogenous wild-type
Htt within the striatum in the rhesus macaque.
The nonallele-selective silencing of ATXN3 with the
replacement of the normal allele
The effective silencing of both alleles of a gene implicated
in a disease can be accompanied by the exogenous expres-
sion of the normal allele to preserve normal protein func-
tion. This so-called replacement strategy was previously
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tested for SCA6 [39,40], ALS (amyotrophic lateral sclero-
sis) [41] and RP (retinitis pigmentosa) [42,43].
We chose the ATXN3 transcript for the evaluation of
this strategy (Figure 1A). First, we tested specific siRNA
for efficient nonallele-selective silencing of ATXN3
expression. Then we cloned the cDNA of ATXN3 con-
taining 8 CAG repeats and introduced specific muta-
tions at the siRNA target sequence to make the exogene
transcript resistant to RNAi. The substitution positions
in the target sequence were 7, 10 and 16 nt from the 5’
end of the antisense siRNA strand. These mutations did
not change the amino acid sequence of ataxin-3.
The testing of the replacement strategy for ATXN3
was performed in HeLa cells due to the significant toxi-
city induced by the plasmid encoding exogenous ataxin-
3 in the SCA3 fibroblasts. The HeLa cells were trans-
fected with ATXN3-specific siRNA and/or ATXN3 plas-
mid (ATXN3-8Q), and the ataxin-3 level was monitored
by western blotting. Co-transfection with siRNA and the
ATXN3 plasmid resulted in a significant reduction of
endogenous ataxin-3 (22 Q) and the simultaneous
expression of exogenous ataxin-3 (8 Q) at a level com-
parable to that of the endogene (Figure 1B). This effect
obtained in the HeLa cell model system represents
anticipated results of the replacement strategy, indicat-
ing that this approach is feasible.
The main advantage of the replacement strategy is
that it provides the allele-specific effect of normal/
mutant protein expression without the need to design
allele-discriminating reagents. The main challenge of
this approach is to obtain the appropriate level of exo-
gene expression, which would correspond to the endo-
gene expression level.
The allele-selective silencing of polyQ genes by SNP-
targeting
The SNP-targeting strategy is based on the ability of
RISC to discriminate between two alleles of a gene that
differ by a single nucleotide in the target sequence.
When the siRNA guide strand is fully complementary to
the mutant transcript, cleavage will occur. Otherwise, a
single-nucleotide mismatch with the normal transcript
can inhibit or prevent the cleavage reaction.
There are several guidelines for the design of SNP-tar-
geting siRNAs based on the testing of RNAi reagents for
specific genes and SNPs [20,21] and based on systematic
large-scale studies [44,45]. These guidelines include the
preferential positioning of mismatch (mainly central),
the type of siRNA/mRNA mismatch (preferably purine-
purine) and the possible introduction of additional
mismatches.
Additionally, different guidelines for specific siRNA
design can be used in the development of SNP-targeting
siRNAs (reviewed in [46,47]). These guidelines include
the manipulation of the siRNA length, the introduction
of thermodynamic asymmetry into the siRNA duplex
and the chemical modification of siRNA strands [48-53].
Different approaches can be tested to increase the effi-
ciency and allele selectivity of the reagent. The efficiency
is primarily enhanced by an increase in reagent stability
or by making the antisense strand preferential for RISC
loading.
Here, we show examples of the SNP-based approach
for SCA3, HD and SCA1. The SCA1 model is evaluated
in this strategy for the first time and the specific HTT
SNP has not been investigated in previous studies.
First, we screened the HTT, ATXN1 and ATXN3
genes in the HD, SCA1 and SCA3 fibroblast cells,
respectively, in search of suitable SNP variants that
would differ between the normal and the mutant allele.
Several cell lines were tested to find the heterozygous
SNPs and the colocalization of SNP variants with either
normal or mutant allele was demonstrated (Additional
file 2: Supplementary Table 1 and Supplementary
Methods).
Targeting ATXN3 SNP in SCA3 cells
For ATXN3 targeting, we selected the SNP that was
used by others in exogenous models [24-26]. The
selected SNP (rs12895357) is located at the 3’ end of the
repeat tract, and its G and C variants were shown to be
associated with the normal and mutant alleles, respec-
tively [25,54]. Worldwide, 70% of disease chromosomes
carry the C variant which makes this SNP a promising
target for this strategy [55]. Following the existing
guidelines, we designed 7 siRNAs that are mismatched
with the normal allele at positions 9 (G9), 10 (G10), 12
(G12) or 16 nt (G16) from the 5’ end of the antisense
siRNA strand (Figure 2A). We tested three variants of
Figure 1 The replacement strategy tested for ATXN3. (A) The
target site and nucleotide sequence of siRNA directed at the ATXN3
transcript. (B) The western blot analysis of the ataxin-3 levels in the
HeLa cells at 72 h after transfection with 100 nM siRNA SCA3 and/
or ATXN3-8Q plasmid. C - the reference line shows the ATXN3
expression level in the cells transfected with control siRNA. The
GAPDH protein level was used as a loading control.
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the G9 siRNA: one with a mismatch in the siRNA
duplex (G9M); a second with shorter, 18-nt strands
(G9S); and a third with longer, 27-nt strands (G9L). The
siRNAs were transfected into the SCA3 cells (GM06153,
18/69 CAG in ATXN3 mRNA) at 50 nM. The ATXN3
mRNA and protein levels were assessed using RT-PCR
and western blot, respectively (Figure 2B, C). All of the
siRNAs were effective in mutant ATXN3 silencing,
decreasing the mutant ataxin-3 levels to approximately
25% of the control level. Most of 7 siRNAs showed
some allele-discriminating properties, with very high
allele selectivity observed for G9, G9M, G9S and G10.
The length-modified duplexes, G9S and G9L, showed
decreased and increased silencing activity, respectively.
This finding agrees with the effects typically observed
after changes in siRNA length. The G9 and G10 siRNAs
were then tested over a broader range of concentrations
from 2 to 200 nM. Both siRNAs showed significant
allele discrimination in ataxin-3 silencing for all of the
concentrations tested (Figure 2C, D). The G9 siRNA
showed higher efficiency in mutant allele silencing, with
an ~80% reduction of mutant ataxin-3 even at 2 nM.
For both siRNAs, normal ataxin-3 was retained to at
least 60% of the control level even at 200 nM.
Figure 2 The activity of siRNAs targeting SNP sites in the SCA3 model. (A) The target sites and nucleotide sequences of siRNAs directed at
rs12895357 SNP in the ATXN3 gene. The nucleotide in the antisense strand of siRNA that directly targets the SNP site is marked in bold. The
mismatches introduced into siRNA duplex are in gray boxes. RNA is in lowercase; DNA is in uppercase. (B) The RT-PCR analysis of ATXN3
expression at the transcript level in the SCA3 fibroblasts (GM06153) at 72 h after transfection with 50 nM siRNAs. (C) The western blot analysis of
the ataxin-3 levels for the experiment described in (B). (D) The western blot analysis of the ataxin-3 levels in the SCA3 fibroblasts at 72 h after
transfection with 2, 10, 50 or 200 nM siRNA G9. (E) The western blot analysis as in (D) for siRNA G10. C - the reference bar indicates the ATXN3
expression level in the cells transfected with control siRNA. In the graphs, the signal intensities were normalized to GAPDH mRNA or protein
levels and compared using a one-sample t-test. The error bars represent the standard deviations. The P-value is indicated by asterisks (* p <
0.001; ** 0.001 < p < 0.05).
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Targeting HTT SNPs in HD cells
To test the SNP-targeting strategy in the HD cellular
model, we chose C/T SNP (rs1065745) located ~1 kb
from the CAG repeat tract. Average heterozygosity of
the SNP is 0,152 and the frequency of the minor allele
T varies from 0% in European and Asian populations to
19,3% in Sub-Saharan African populations (NCBI
dbSNP). We designed siRNAs with mismatches to the
normal allele at positions 9 (G9), 10 (G10) or 16 nt
(G16) (Additional file 3: Figure S2A). We also designed
three variants of the G10 siRNA: two with additional
mismatches in the target sequence (G10M1 and
G10M2) and a duplex composed of 18-nt strands
(G10S). The siRNAs were transfected into the HD cells
(GM04208, 21/44 CAG in HTT mRNA) at 50 nM, and
the HTT mRNA level was assessed using RT-PCR
(Additional file 3: Figure S2B). Considerable allele selec-
tivity was observed for the G16 siRNA. The other siR-
NAs showed either no allele-discriminating properties
or no activity at all. We tested the HTT transcript and
protein silencing by G16 over a broader range of con-
centrations from 2 to 200 nM (Additional file 3: Figure
S2C, D). The G16 siRNA showed significant allele-dis-
criminating properties at all of the concentrations tested,
decreasing the normal mRNA to no more than 80% of
the control level and silencing the mutant allele to
~40% of the control level. Next, we assessed protein
inhibition by G16. Mutant allele expression was ana-
lyzed using a polyQ-specific antibody, and the whole-
HTT level was analyzed using a huntingtin-specific anti-
body, which showed a decrease in the mutant protein
level (Additional file 3: Figure S2D).
Targeting ATXN1 SNP in SCA1 cells
In the SCA1 model, we tested C/T SNP (rs179990) tar-
geting. This SNP with an average heterozygosity of 0,41
is located ~250 nt from the CAG repeat tract. The
minor allele T occurs with about 30% frequency in ESP
cohort populations (the group includes some of the lar-
gest well-phenotyped populations in the United States)
(NCBI dbSNP). We designed four siRNAs with mis-
matches relative to the normal allele at positions 9 (G9),
10 (G10), 11 (G11) or 16 nt (G16) (Additional file 4:
Figure S3A). The siRNAs were transfected into SCA1
fibroblasts (GM06927, 29/43 CAG in ATXN3 mRNA) at
50 nM. The ATXN1 mRNA level was assessed using
RT-PCR (Additional file 4: Figure S3B). All of the siR-
NAs showed relatively low efficiency in the silencing of
the ATXN1 alleles with no more than a 60% reduction
in the mRNA level. We only observed considerable
allele selectivity for G10. We tested this siRNA over a
broader range of concentrations (Additional file 4: Fig-
ure S3C). At 200 nM, there were ~20% and ~60%
reductions in the normal and mutant allele levels,
respectively. Significant allele discrimination in ATXN1
silencing was observed at all of the G10 concentrations
tested.
The evaluation of SNP targeting
The SNP variants in the SCA3 model (18CAG/G and
69CAG/C) offer better properties for allele discrimina-
tion by siRNA because strong purine-purine mismatches
(G-G, siRNA-normal allele target) can be introduced.
For SNPs in the models of HD (21CAG/T and 44CAG/
C) and SCA1 (29CAG/T and 43CAG/C), we were able
to analyze allele selectivity based on the discrimination
between G-U (weak) pairing on normal allele and G-C
(strong) pairing on mutant allele. Nevertheless, for all of
the models tested, the siRNAs showing considerable
allele-discriminating properties were selected. The best
performing reagents have a mismatch position located
in the central part of the antisense strand (at position 9
or 10 counting from the 5’-end). For the HD model, the
relevance of position 16 was confirmed [21].
A serious limitation of the SNP-targeting strategy is
the restriction in the choice of the target sequence.
Some regions containing SNPs may not be convenient
targets for siRNAs, which may explain the low efficiency
of the ATXN1-directed reagents in our experiments. We
expected that for shorter siRNA duplexes, a 1-nt mis-
match could result in stronger allele discrimination.
However, for G9S and G10S, we only observed
decreased activity with no improvement in the allele
selectivity in ATXN3 and HTT silencing, respectively.
The existing guidelines for the design of SNP-targeting
reagents are still not precise, and for most SNPs, a set of
siRNAs must be tested to find the reagent that possesses
the desired activity. Moreover, there may be problems
with ensuring the long-term allele-selective silencing
effects with shRNAs in the SNP-targeting strategy.
shRNA is processed in cells by the RNase Dicer to gen-
erate siRNAs. It is difficult to predict the exact position
of Dicer cleavage, and multiple cleavages often occur
that differ by 1 or 2 nts [56,57]. For SNP-targeting
siRNA, the effect of 1- or 2-nt differences in the mis-
match position can result in a loss of allele-selective
activity. Despite these limitations, allele-discriminating
shRNAs based on SNP-targeting have been previously
described [24].
Repeat-region targeting for HTT silencing
Triplet repeat expansion can also be targeted by differ-
ent oligonucleotide reagents. This straightforward strat-
egy has some limitations resulting from the high
frequency of relatively long CAG repeat tracts in normal
transcripts [58]. Human genome encodes about 200
mRNAs harboring CAG repeats and about 100 mRNAs
containing CUG repeats longer than 6 repeated units
and transcripts having these sequences are potential
unintended targets of regular CAG/CUG siRNAs (off-
Fiszer et al. BMC Molecular Biology 2012, 13:6
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target effect). This effect is much less pronounced for
modified siRNAs functioning like miRNAs and inhibit-
ing translation rather than inducing mRNA cleavage.
Therefore, gene selectivity and allele selectivity of silen-
cing is more difficult to achieve in this case. Several
RNAi reagents and chemically modified antisense
reagents have been used for targeting of the repeat
region in AR, ATXN3, ATXN1 and HTT
[26,30,32,33,59,60].
Targeting CAG repeats by antisense reagents
Antisense oligonucleotides (ASOs) can be designed to
silence the expression of polyQ-related genes according
to different mechanisms, e.g., through translational
blockade or RNaseH activation. There is also a large
variety of chemical modifications that can be introduced
into the reagent sequence. Here, we tested a set of
CAG-repeat-targeting reagents, which included different
mixmers containing LNA modifications. These reagents
possessed pure DNA or RNA sequences in the central
region (DNA/LNA gap and RNA/LNA gap) to activate
specific RNA-RNA- or DNA-RNA-dependent cleavages
of mRNA. We also designed oligomers containing
2’OMe (2’OMethylo), PTO (phosphothio) and morpho-
lino modifications. All of the reagents are presented in
Figure 3A. Our experiments also included the use of
CAG/CUG siRNA (d7) [26,30], DNA/LNA 7 and PNA
[32].
The oligomers were transfected into HD fibroblasts
(GM04281, 17/68 CAG in HTT mRNA) at 50 nM, with
the exception of PNA and the morpholino, which were
delivered to cells at 2 μM and 20 μM, respectively. The
huntingtin level was assessed by western blotting 72 h
after transfection (Figure 3B). Most of the reagents
showed silencing of both alleles of HTT or no activity at
all. High allele selectivity was demonstrated for morpho-
lino and was confirmed for PNA (Figure 3C). Both oli-
gomers showed similar inhibitory properties with a
decrease of mutant huntingtin to ~25% of the control
level and normal allele silencing to no more than 70%
of the control level.
In the cell culture experiments, PNAs and morpholi-
nos are very difficult to deliver. Cell entry of these
uncharged oligomers was facilitated by Endo-Porter
delivery of the morpholinos and the addition of lysine
residues to the PNAs. Very high concentrations were
still required in the cell culture medium to observe any
silencing effects. Nevertheless, the methods of delivery
for such oligomers are under development [61], to take
better advantage of their allele-selective activity.
Targeting CAG repeats by siRNA and miRNA-like reagents
High allele discrimination by repeat-region targeting
cannot be achieved by typical RNAi reagents because
siRNAs composed of CAG/CUG strands efficiently
silence the expression of mutant and normal HTT and
ATXN3 alleles [26,30,32]. We also characterized the
activity of CAG/CUG siRNAs and showed that both
strands of this duplex are active in the silencing of sev-
eral other normal transcripts containing complementary
repeats [30]. We and others have shown recently that
the sequence modification of CAG/CUG siRNA results
in allele-selective huntingtin inhibition [30,33]. These
so-called miRNA-like reagents were designed to contain
Figure 3 Chemically modified oligomers as huntingtin inhibitors. (A) The sequences of oligomers with indicated chemical modifications at
particular positions. (B) The western blot analysis of huntingtin levels in the HD fibroblasts (GM04281) at 72 h after transfection with the
indicated oligomers. (C) Representative results for the experiment described in (B) for allele-selective oligomers: PNA and morpholino. C - the
reference bar indicates the HTT expression level in the cells transfected with control siRNA. In the graph, the signal intensities were normalized
to the plectin protein level and compared using a one-sample t-test. The error bars represent standard deviations. The P-value is indicated by
asterisks (* p < 0.001; ** 0.001 < p < 0.05).
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mismatches with the target sequence at specific posi-
tions, and they were found to be active at the level of
the inhibition of mutant protein translation. In Figure 4,
we summarize the tested approaches with RNA
duplexes targeting CAG repeats in the HTT transcript,
including our newly designed reagents, the so-called
self-duplexing miRNAs (sd-miRNAs, Fiszer et al., manu-
script submitted). The self-duplexing miRNAs are a new
class of silencing reagents composed of CUG repeats
that contain one or more U-base substitutions increas-
ing the ability of oligoribonucleotide to form self-duplex
structure. These guide-strand-only reagents show lower
toxicity than regular siRNA and miRNA-like duplexes
composed of both the CUG and CAG repeat strands.
Challenges connected with testing the repeat-targeting
reagents
There are some difficulties involved with assessing the
silencing activity of repeat-targeting reagents. We found
that standard RT-PCR might be an unreliable method
for the assessment of the potential degradation of tran-
scripts targeted by chemically modified oligomers when
the amplification includes the repeat region. The results,
which indicate a preferential lowering of the mutant
mRNA level by oligomers, may be misleading. This
effect may stem from the inhibition of mutant mRNA
reverse transcription by the excess of non-degraded oli-
gomer. The expanded repeat tracts in mRNA offer a
number of binding sites for oligomers composed of
complementary repeats, which may form a strong bar-
rier for reverse transcription. Such misleading results
can also be observed when the cells are transfected with
unmodified single-stranded RNAs and when the repeat-
targeting duplexes used at relatively high concentrations
contain some excess of the single strand. This false
silencing effect can be reversed by the removal of the
short RNA fraction from the total RNA before reverse
transcription (Additional file 5: Figure S4). In some
cases, the removal of strongly bound oligomers may be
difficult or even impossible to achieve. In such cases,
the assessment of the total mRNA level can be per-
formed by RT-PCR outside of the repeat region. How-
ever, the analysis of the protein level is necessary for an
unbiased evaluation of the true silencing effects.
The evaluation of repeat targeting
For triplet-repeat-targeting strategies developed for
polyQ diseases, the factor that enables allele and gene
selectivity is a two- to three-fold difference in the length
of complementary sequence in the normal and mutant
allele [62]. In our study two different types of reagents
composed of trinucleotide repeats were shown to be
allele selective in HTT silencing: antisense oligomers (e.
g., morpholino and PNA) and miRNA-like duplexes.
The overall effect of the activities of these reagents is
similar. The transcript level is not considerably
decreased, whereas an efficient and selective downregu-
lation of mutant protein is observed. In contrast, the
mechanisms of activity for these two types of reagents
are different. The antisense oligomers likely bind to the
repeat tract without proteins, whereas the miRNA-like
reagents interact with the complementary sequence
Figure 4 A comparison of RNA duplexes targeting the CAG repeat tract in HTT. A schematic representation of the duplex sequences (left
panel) and the interaction of the CUG strand with CAG tracts in the HTT transcript (middle panel). The right panel shows our accumulated
results (published elsewhere) of duplex activity toward HTT expression at the mRNA and protein levels in the same experimental setup: 50 nM
concentration of duplexes 72 h after the transfection of the HD cell line (GM04281).
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within the RISC. In each case, the inhibition of mutant
protein translation is achieved, which means that a
translation blockade, e.g. for the 68 Q tract in hunting-
tin, is formed by either ~9 morpholino oligomers or ~3
CUG miRNA-loaded RISCs (according to the reported
argonaute protein footprint on RNA [63]).
It is possible that the selectivity observed for RISC
charged with miRNA-like acting siRNAs is achieved by
cooperative action of silencing complexes, residing side
by side on the repetitive sequence. This kind of syner-
gistic effect was demonstrated for miRISC interaction
with target sequence located within 3’UTR [64-66].
Conclusions
Here we have presented and evaluated several oligonu-
cleotide-based strategies which have been proposed for
the treatment of polyQ diseases. The advantageous fea-
tures of these strategies and their limitations are sum-
marized in Table 1. It is clear that each strategy offers
considerable advantages, and none of them should be
disregarded at this point. These strategies require
further development and testing to assess their potential
therapeutic benefits and better understand their unde-
sired side effects.
For all the approaches specific gene silencing is the
challenge and off-target effects should be carefully ana-
lyzed. The strategies can be designed to target the
mutant allele only or both alleles. Allele-selective strate-
gies were developed for SNP and repeat region-target-
ing. The repeat-targeting strategy is the most universal
approach, and one carefully designed reagent could be
used, in principle, for the treatment of most, if not all,
polyQ diseases. Other strategies can be developed for a
particular disease (nonallele-selective silencing, replace-
ment strategy) or only for a group of patients suffering
from a specific polyQ disorder (SNP-targeting). The
clinically advantageous long-term effects of different
reagents can be obtained either by the chemical modifi-
cations of synthetic reagents or by their cellular expres-
sion from suitable vectors.
Recent research has revealed that the pathogenesis of
polyQ diseases is triggered not only by mutant protein
but also by mutant transcript [67]. The exact contribu-
tion from a mutant transcript to the overall toxic effects,
although unknown at present, needs to be taken into
consideration when selecting and developing further the
therapeutic approaches. The expression of toxic protein
is lowered in each of the proposed strategies, but not all
of them are effective in lowering the mutant transcript
level. The normally expressed mutant transcript may be
blocked from the pathogenic interactions with various
protein factors by the same mechanism (reagent bind-
ing) which inhibits its translation [68]. On the other
hand, transcript degradation and the resulting protein
synthesis inhibition can be achieved by typical RNAi
strategies. Some repeat-targeting miRNA-like reagents
are capable of the specific inhibition of mutant protein
translation, and some other trigger lowering of both,
mutant transcript and protein (unpublished data). Thus,
the rapidly developing technologies designed to inhibit
mutant gene expression offer various options when
applied to the treatment of polyQ diseases. These var-
ious gene silencing options may also be helpful in resol-
ving the issue which has recently gained considerable
importance: what are the shares of mutant transcript
toxicity and mutant protein toxicity in the pathogenesis
of polyQ diseases?
Methods
Cell culture and transfection
Fibroblasts from HD patients (GM04208, 21/44 CAG;
GM04281, 17/68 CAG), SCA1 patients (GM06927, 29
CAG interrupted with 2 CAT/43 CAG) and SCA3
patients (GM06153, 18/69 CAG) (Coriell Cell Reposi-
tories) were grown in EMEM (Lonza) supplemented
with 8% FBS (fetal bovine serum; Sigma-Aldrich), anti-
biotics (Sigma-Aldrich) and non-essential amino acids
(Sigma-Aldrich). HeLa cells were grown in RPMI1640
medium (Lonza) supplemented with 10% FBS, antibio-
tics and vitamins (PAA).
Table 1 A comparison of oligonucleotide-based strategies for polyQ diseases based on the desired properties of the
reagents
PROPERTIES OF REAGENT
STRATEGIES target specificity allele selectivity universality stability in cells delivery in shRNA
Specific silencing by RNAi uncertain no uncertain uncertain yes
Replacement strategy uncertain uncertain uncertain uncertain yes
SNP targeting uncertain yes no uncertain yes
Repeat targeting by siRNA no no yes uncertain yes
Repeat targeting by miRNA uncertain yes yes uncertain yes
Repeat targeting by ASO uncertain yes yes yes no
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The fibroblast cell transfections were performed using
Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s instructions. Briefly, the cells were plated
in 25-cm2 dishes 24 h prior to transfection at ~60%
confluence. The transfection mixtures were prepared in
EMEM with 5 μl of Lipofectamine, and the medium was
changed 4 h after transfection. HeLa 229 cells LGC
(Promochem, ATCC number: CCL-2.1) were transfected
in 6-well plates with 100 nM siRNAs and 1 μg of plas-
mid per well using 2 μl of jetPRIME (Polyplus Transfec-
tion) according to the manufacturer’s instructions. The
efficiency of transfections was monitored using a
BlockIT fluorescent siRNA (Life Technologies). The
morpholino oligomers were diluted to 20 μM with 10
μM Endo-Porter (Gene Tools) in complete medium and
added to the cells. Morpholino delivery was monitored
using oligomer with 3’ fluorescein. The PNA oligomers
were diluted to 2 μM in EMEM and added to the cells
with a medium exchange after 24 h.
All of the unmodified RNA oligonucleotides were
synthesized by Metabion. The chemically modified oli-
gomers were synthesized by Sigma-Aldrich, PANA-
GENE, Exiqon or Gene Tools. The sequences of the
synthetic oligomers used in this study are presented in
Figures. The siRNAs were annealed prior to transfec-
tion, by being combined in annealing buffer (Metabion)
to a duplex concentration of 20 μM and incubated at
90°C for 1 minute and then at room temperature for 45
minutes. The formation of duplexes was confirmed by
migration analysis (vs. single strands) in 2.5% agarose
gel stained with GelRed (Biotium).
RNA isolation and RT-PCR
Total RNA was isolated from cells using TRI Reagent
(BioShop) according to the manufacturer’s instructions.
The RNA concentration was measured using a Nano-
Drop spectrophotometer. A total of 500 ng of RNA was
reverse transcribed using Superscript II (Life Technolo-
gies) and random hexamer primers (Promega). The
quality of the reverse transcription (RT) reaction was
assessed using amplification of the GAPDH housekeep-
ing gene. The primer sequences and their respective
PCR products are listed in Additional file 2: Table S2.
The reaction products were separated on 1.5% agarose
gels in 0.5× TBE buffer and stained with ethidium
bromide.
Protein isolation and western blot
The cells were lysed in buffer containing 60 mM TRIS-
base, 2% SDS, 10% sucrose and 2 mM PMSF. The pro-
tein concentration was estimated using a NanoDrop
spectrophotometer. A total of 20 μg of protein was
diluted in sample buffer containing 2-mercaptoethanol
and boiled for 5 minutes. For ataxin-3 detection, the
proteins were separated using Tris-HCl SDS-polyacryla-
mide gel electrophoresis (5% stacking/12% resolving gel)
in Laemmli buffer. For huntingtin electrophoresis, a
Tris-acetate SDS-polyacrylamide gel was used (5% stack-
ing/4% resolving gel). After electrophoresis, the proteins
were wet-transferred to a nitrocellulose membrane. All
of the immunodetection steps were performed on an
SNAPid (Millipore) in buffer containing 0.25% nonfat
milk in PBS/0.1% Tween 20. For ataxin-3/GAPDH
detection, the blots were probed with the primary anti-
bodies anti-ataxin-3 (1:1000, MAB5360, Millipore) and
anti-GAPDH (1:5000, MAB374, Millipore). The blots
were then treated with a biotinylated secondary antibody
(1:500, B7264, Sigma-Aldrich) and incubated with a
streptavidin-AP (alkaline phosphatase) conjugate
(1:2000, Millipore). The immunoreaction was detected
using the BCIP/NBT substrate (Sigma-Aldrich). For
huntingtin and plectin detection, the blots were probed
with the primary antibodies: anti-huntingtin (1:1000,
MAB2166, Millipore) and anti-plectin (1:1000, ab83497,
Abcam), and then with HRP-conjugated secondary anti-
bodies (1:500, A9917, Sigma-Aldrich; 711035152, Jack-
son ImmunoResearch). The immunoreaction was
detected using the ChemiFast Chemiluminescent Sub-
strate (SYNGENE).
The construction of the ATXN3 plasmid
The cDNA sequence of ataxin-3 (~1.8 kb) containing 8
CAG repeats was cloned into a pGEM-T Easy vector
(Promega). Site-directed mutagenesis of an insert was
performed with primers MUT_R and MUT_F
(sequences given in Additional file 2: Table S2) using a
Phusion Kit (Finnzymes). The mutated ATXN3 insert
was then cloned into pIRES2-AcGFP1 (Clontech) using
NheI and SacI restriction enzymes (Fermentas).
Statistical analysis
All experiments were repeated at least three times. The
statistical significance of silencing was assessed with a
one-sample t-test with the hypothetical value of 1
assigned to cells treated with control siRNA (C).
Selected data were compared using an unpaired t-test.
Two-tailed P values of less than 0.05 were considered
significant.
Additional material
Additional file 1: Figure S1. The activity of siRNAs targeting both alleles
of HTT. (A) The target sites and nucleotide sequences of siRNAs directed
at the mRNA of the HTT gene (lowercase for RNA, uppercase for DNA).
(B) The RT-PCR analysis of HTT expression at the transcript level in the
HD fibroblasts (GM04281) transfected with 50 nM siRNA HD1 at the
indicated time points. (C) The western blot analysis of the huntingtin
levels for the experiment described in (B). (D) The RT-PCR analysis of the
HTT transcript levels in the HD fibroblasts (GM04281) at 72 h after
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transfection with 50 nM siRNAs HD1, HD2 and HD3. (E) The western blot
analysis of the huntingtin levels in the HD fibroblasts (GM04281) at 72 h
after transfection with 2, 10 or 50 nM siRNA HD1. C - the reference bar
indicates the HTT expression level in the cells transfected with control
siRNA. In the graphs, the signal intensities were normalized to GAPDH
mRNA or protein levels and compared using a one-sample t-test. The
error bars represent standard deviations. The P-value is indicated by
asterisks (* p < 0.001; ** 0.001 < p < 0.05).
Additional file 2: Supplementary methods and supplementary
tables.
Additional file 3: Figure S2. The activity of siRNAs targeting SNP sites in
the HD model. (A) The target sites and nucleotide sequences of the
siRNAs directed at rs1065745 SNP in the HTT gene. The nucleotides in
the antisense strand that directly interact at the SNP site and additional
mismatches with the target sequence are marked in bold. The
mismatches introduced into the siRNA duplex are in gray boxes. RNA is
in lowercase; DNA is in uppercase. (B) The RT-PCR analysis of the HTT
expression at the transcript level in the HD fibroblasts (GM04208) at 72 h
after transfection with 50 nM siRNAs. (C) The RT-PCR analysis of the HTT
transcript level in the HD fibroblasts at 72 h after transfection with 2, 10,
50 or 200 nM siRNA G16. (D) The western blot analysis for the
experiment described in (C). C - the reference bar indicates the HTT
expression levels in the cells transfected with control siRNA. In the
graphs, the signal intensities were normalized to GAPDH mRNA level and
compared using a one-sample t-test. The error bars represent the
standard deviations. The P-value is indicated by asterisks (* p < 0.001; **
0.001 < p < 0.05).
Additional file 4: Figure S3. The activity of siRNAs targeting SNP sites in
the SCA1 model. (A) The target sites and the nucleotide sequences of
siRNAs directed at the rs179990 SNP in the ATXN1 gene. The nucleotides
in the antisense strand that directly interact at the SNP site are marked
in bold. The mismatches introduced into the siRNA duplex are in gray
boxes. RNA is in lowercase; DNA is in uppercase. (B) The RT-PCR analysis
of ATXN1 expression at the transcript level in the SCA1 fibroblasts
(GM06927) at 72 h after transfection with 50 nM siRNAs. (C) The RT-PCR
analysis of ATXN1 transcript level in the SCA1 fibroblasts at 72 h after
transfection with 2, 10, 50 or 200 nM siRNA G10. C - the reference bar
indicates the ATXN1 expression level in the cells transfected with the
control siRNA. In the graphs, the signal intensities were normalized to
the GAPDH mRNA level and compared using a one-sample t-test. The
error bars represent standard deviations. The P-value is indicated by
asterisks (* p < 0.001; ** 0.001 < p < 0.05).
Additional file 5: Figure S4. Difficulties in the RT-PCR including the
amplification of the expanded repeat tract. The RT-PCR analysis of the
HTT alleles’ transcript levels in the HD fibroblasts (GM04281) at 24 h after
transfection with 10 nM control siRNA (C) or RNA (CUG)7. The two lanes
on the left represent RT-PCR performed in standard conditions. The two
lanes on the right include RNA purification from the fraction of short
RNAs before RT-PCR.
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